Novan to Present Positive Phase 2 Results for SB208 Antifungal Program at Winter Clinical Dermatology Conference

Topical Nitric Oxide-Releasing Gel Shows Antifungal Activity in Tinea Pedis Infections

Novan, Inc. today announced that Phase 2 efficacy and safety data for SB208, a topical, silicone-based gel under development for the treatment of fungal infections of the skin and nails, such as tinea pedis, or athlete’s foot, and onychomycosis, will be presented at the Winter Clinical Dermatology Conference to be held January 12th through the 17th in Maui, Hawaii.

Read the full press releaseCompany website